HOME >> MEDICINE >> NEWS
Initial chemotherapy treatment reduces relapses in MS patients

DENVER, CO Mitoxantrone, a chemical routinely used to fight breast cancer, leukemia and malignant lymphoma, has found a new disease to battle: Multiple Sclerosis. Used in an initial intensive course of chemotherapy (induction therapy), mitoxantrone dramatically decreases disease activity in MS patients for at least four years, according to a study presented at the Annual Meeting of the American Academy of Neurology.

Induction therapy, frequently used against cancers, is designed to wipe out abnormal cells and allow for the regrowth of normal cells. Mitoxantrone for the treatment of MS has recently been approved by the U.S. Food and Drug Administration. It has been used to treat MS in France for more than a decade. Researchers from CHU Pontchaillou of Rennes, France, have demonstrated that mitoxantrone induction therapy for relapsing-remitting MS patients has produced dramatic results in disease activity.

Over the past ten years, 100 worsening relapsing-remitting MS patients were given initial mitoxantrone induction therapy for six months, with mitoxantrone combined with methylprednisolone administered intravenously on a monthly schedule. The annual relapse rate decreased significantly from 3.20 during the 12 months preceding mitoxantrone onset to 0.30 during the first year following induction onset, corresponding to a reduction of nearly 90 percent that was maintained for more than five years. The percentage of relapse-free patients was 76 percent at one year of follow-up, and was maintained at 64 percent, 45 percent, and 43 percent at years two, three and four, respectively, with a median time to the first relapse of 2.8 years.

The clinical benefit and reduction of disease activity supports our belief that mitoxantrone, as administered in this study, may be an effective induction treatment before initiating other long-term disease modifying therapies for worsening relapsing-remitting MS patients, commented study author Emmanuelle Le Pa
'"/>

Contact: Cheryl Alementi
calementi@aan.com
651-695-2737
American Academy of Neurology
17-Apr-2002


Page: 1 2

Related medicine news :

1. Initial findings of first comprehensive study into ageing process published
2. Initial Avon/NCI breast cancer research grants awarded in Progress for Patients awards program
3. Initially recommended drug dosages often too high, study finds
4. Initial clinical study shows safety and bioactivity of cancer vaccine
5. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
6. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
7. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
8. Older women can benefit from chemotherapy to treat breast cancer
9. Resistance to chemotherapy
10. New treatment rivals chemotherapy for lymphoma, U-M study finds
11. Adding radiation therapy to chemotherapy improves survival in patients with high-risk breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... a national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel ... also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
Breaking Medicine Technology:
Cached News: